Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV Challenge
Barbara K. Felber, Zhongyan Lu, Xintao Hu, et al.
Cell Reports (2020) Vol. 31, Iss. 6, pp. 107624-107624
Open Access | Times Cited: 52

Showing 1-25 of 52 citing articles:

A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques
Peng Zhang, Elisabeth Narayanan, Qingbo Liu, et al.
Nature Medicine (2021) Vol. 27, Iss. 12, pp. 2234-2245
Open Access | Times Cited: 120
Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals
Savannah E. Butler, Andrew R. Crowley, Harini Natarajan, et al.
Frontiers in Immunology (2021) Vol. 11
Open Access | Times Cited: 115
Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB/MF59 Vaccine
Xintao Hu, Krithika P. Karthigeyan, Savannah Herbek, et al.
The Journal of Infectious Diseases (2024) Vol. 230, Iss. 2, pp. 455-466
Closed Access | Times Cited: 22
The mRNA-1647 vaccine: A promising step toward the prevention of cytomegalovirus infection (CMV)
Adewunmi Akingbola, Abiodun Adegbesan, Olajumoke Adewole, et al.
Human Vaccines & Immunotherapeutics (2025) Vol. 21, Iss. 1
Open Access | Times Cited: 1
Immunization with germ line–targeting SOSIP trimers elicits broadly neutralizing antibody precursors in infant macaques
Ashley N. Nelson, Xiaoying Shen, Sravani Vekatayogi, et al.
Science Immunology (2024) Vol. 9, Iss. 98
Closed Access | Times Cited: 6
Increased Chemokine Production is a Hallmark of Rhesus Macaque Natural Killer Cells Mediating Robust Anti-HIV Envelope-Specific Antibody-Dependent Cell-Mediated Cytotoxicity
Junsuke Nohara, Tyler Evangelous, Madison Berry, et al.
Pathogens and Immunity (2025) Vol. 10, Iss. 1, pp. 49-79
Closed Access
New SHIVs and Improved Design Strategy for Modeling HIV-1 Transmission, Immunopathogenesis, Prevention, and Cure
Hui Li, Shuyi Wang, Fang-Hua Lee, et al.
Journal of Virology (2021) Vol. 95, Iss. 11
Open Access | Times Cited: 32
Self-Assembled Particles Combining SARS-CoV-2 RBD Protein and RBD DNA Vaccine Induce Synergistic Enhancement of the Humoral Response in Mice
M. B. Borgoyakova, Л. И. Карпенко, А. П. Рудометов, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 4, pp. 2188-2188
Open Access | Times Cited: 22
Lessons from Acquired Natural Immunity and Clinical Trials to Inform Next-Generation Human Cytomegalovirus Vaccine Development
Xintao Hu, Hsuan-Yuan Wang, Claire E. Otero, et al.
Annual Review of Virology (2022) Vol. 9, Iss. 1, pp. 491-520
Open Access | Times Cited: 19
Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV gag conserved elements in macaques
Antonio Valentin, Cristina Bergamaschi, Margherita Rosati, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 18
Positive-unlabeled learning to infer protection status and identify correlates in vaccine efficacy field trials
Shiwei Xu, Natasha S. Kelkar, Margaret E. Ackerman
iScience (2024) Vol. 27, Iss. 3, pp. 109086-109086
Open Access | Times Cited: 3
Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses than that of the Partially Effective gB/MF59 Vaccine
Xintao Hu, Krithika P. Karthigeyan, Savannah Herbek, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 9
Targeting Fc effector function in vaccine design
Simone I. Richardson, Penny L. Moore
Expert Opinion on Therapeutic Targets (2021) Vol. 25, Iss. 6, pp. 467-477
Closed Access | Times Cited: 21
704/DNA vaccines leverage cytoplasmic DNA stimulation to promote anti-HIV neutralizing antibody production in mice and strong immune response against alpha-fetoprotein in non-human primates
Thibault Colombani, Thomas Haudebourg, Bruno Pitard
Molecular Therapy — Nucleic Acids (2023) Vol. 32, pp. 743-757
Open Access | Times Cited: 8
Polytopic fractional delivery of an HIV vaccine alters cellular responses and results in increased epitope breadth in a phase 1 randomized trial
Maurine D. Miner, Allan C. deCamp, Nicole Grunenberg, et al.
EBioMedicine (2024) Vol. 100, pp. 104987-104987
Open Access | Times Cited: 2
SARS-CoV-2 vaccination elicits broad and potent antibody effector functions to variants of concern in vulnerable populations
Andrew P. Hederman, Harini Natarajan, Leo Heyndríckx, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 7
Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall response
LaTonya D. Williams, Xiaoying Shen, Sheetal Sawant, et al.
PLoS Pathogens (2023) Vol. 19, Iss. 5, pp. e1011359-e1011359
Open Access | Times Cited: 5
Recent insights into Fc-mediated effector responses to HIV-1
Margaret C. Carpenter, Margaret E. Ackerman
Current Opinion in HIV and AIDS (2020) Vol. 15, Iss. 5, pp. 282-289
Open Access | Times Cited: 14
Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques
Margherita Rosati, Mahesh Agarwal, Xintao Hu, et al.
PLoS Pathogens (2021) Vol. 17, Iss. 9, pp. e1009701-e1009701
Open Access | Times Cited: 13
Selection of HIV Envelope Strains for Standardized Assessments of Vaccine-Elicited Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies
Dieter Mielke, Sherry Stanfield-Oakley, Bhavesh Borate, et al.
Journal of Virology (2021) Vol. 96, Iss. 2
Open Access | Times Cited: 13
Safety and Broad Immunogenicity of HIVconsvX Conserved Mosaic Candidate T-Cell Vaccines Vectored by ChAdOx1 and MVA in HIV-CORE 006: A Double-Blind, Randomized, Placebo-Controlled Phase 1 Trial in Healthy Adults Living Without HIV-1 in Eastern and Southern Africa
Chama Chanda, Freddie Kibengo, Michael Mutua, et al.
(2024)
Closed Access | Times Cited: 1
Impact of Recombinant VSV-HIV Prime, DNA-Boost Vaccine Candidates on Immunogenicity and Viremia on SHIV-Infected Rhesus Macaques
Alice Berger, Jannie Pedersen, Monika M. Kowatsch, et al.
Vaccines (2024) Vol. 12, Iss. 4, pp. 369-369
Open Access | Times Cited: 1
Immunogenicity, safety, and efficacy of sequential immunizations with an SIV-based IDLV expressing CH505 Envs
Maria Blasi, Donatella Negri, Kevin O. Saunders, et al.
npj Vaccines (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 13
Effects of persistent modulation of intestinal microbiota on SIV/HIV vaccination in rhesus macaques
Nichole R. Klatt, Courtney A. Broedlow, Jessica M. Osborn, et al.
npj Vaccines (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 12
ADCC-mediating non-neutralizing antibodies can exert immune pressure in early HIV-1 infection
Dieter Mielke, Gama Bandawe, Jie Zheng, et al.
PLoS Pathogens (2021) Vol. 17, Iss. 11, pp. e1010046-e1010046
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top